Endocrine oncology (Bristol, England)

Keyphrases

Publications

volume 4, number 1, 2024

Catherine M Skefos, Pamela L Brock, Erica Blouch, Samantha E Greenberg
SDHA secondary findings in germline testing: counseling and surveillance considerations. Endocrine oncology (Bristol, England) 4 (1) (2024)
Leo D Baxendale-Smith, Karim El-Shakankery, James Gordon-Smith, Lucy Wall
Adrenocortical carcinoma: selective internal radiation therapy and liver metastases. Endocrine oncology (Bristol, England) 4 (1) (2024)
Dheeratama Siripongsatian, Quido G de Lussanet de la Sablonière, Frederik Anton Verburg, Tessa Brabander
How to design a theranostic trial? Endocrine oncology (Bristol, England) 4 (1) (2024)
Yasuhiro Miki, Erina Iwabuchi, Chihiro Inoue, Yuto Yamazaki, Takashi Suzuki
Histopathological analysis potential for unveiling hormone signaling in endocrine-related tumors. Endocrine oncology (Bristol, England) 4 (1) (2024)
Jose E Nunez, Sylvia Ng, Hanbo Chen, Simron Singh, Julie Hallet, Calvin Law, Sten Myrehaug
Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT. Endocrine oncology (Bristol, England) 4 (1) (2024)
Prabesh Khatiwada, Ujjwal Rimal, Zhengyang Han, Lirim Shemshedini
MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer. Endocrine oncology (Bristol, England) 4 (1) (2024)
Mark Simon Stein, Victor Kalff, Scott G Williams, Declan G Murphy, Peter G Colman, Michael S Hofman
The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer. Endocrine oncology (Bristol, England) 4 (1) (2024)
Vasiliki Venetsanaki, Eleana Zisimopoulou, Chrysanthi Zouli, Maria Boudina, Konstantinos Gkiouras, Persefoni Xirou, Aimilia Fotiadou, Mariana Stamati, Elpiniki Argyropoulou, Alexandra Chrisoulidou
Mönckeberg sclerosis in patients with thyroid papillary carcinoma. Endocrine oncology (Bristol, England) 4 (1) (2024)
Leo D Baxendale-Smith, Karim El-Shakankery, James Gordon-Smith, Lucy Wall
Adrenocortical carcinoma: selective internal radiation therapy and liver metastases. Endocrine oncology (Bristol, England) 4 (1) (2024)
Jose E Nunez, Sylvia Ng, Hanbo Chen, Simron Singh, Julie Hallet, Calvin Law, Sten Myrehaug
Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT. Endocrine oncology (Bristol, England) 4 (1) (2024)
Prabesh Khatiwada, Ujjwal Rimal, Zhengyang Han, Lirim Shemshedini
MDM2 regulates the stability of AR, AR-V7, and TM4SF3 proteins in prostate cancer. Endocrine oncology (Bristol, England) 4 (1) (2024)
Catherine M Skefos, Pamela L Brock, Erica Blouch, Samantha E Greenberg
SDHA secondary findings in germline testing: counseling and surveillance considerations. Endocrine oncology (Bristol, England) 4 (1) (2024)
Vasiliki Venetsanaki, Eleana Zisimopoulou, Chrysanthi Zouli, Maria Boudina, Konstantinos Gkiouras, Persefoni Xirou, Aimilia Fotiadou, Mariana Stamati, Elpiniki Argyropoulou, Alexandra Chrisoulidou
Mönckeberg sclerosis in patients with thyroid papillary carcinoma. Endocrine oncology (Bristol, England) 4 (1) (2024)
Dheeratama Siripongsatian, Quido G de Lussanet de la Sablonière, Frederik Anton Verburg, Tessa Brabander
How to design a theranostic trial? Endocrine oncology (Bristol, England) 4 (1) (2024)
Patricia Gina Lu, Zhi Ven Fong, Patrick T Hangge, Yu-Hui Chang, Elisabeth S Lim, Nabil Wasif, Patricia A Cronin, Chee-Chee Stucky
Differential utilization of thyroid lobectomy after the 2015 American Thyroid Association guideline update. Endocrine oncology (Bristol, England) 4 (1) (2024)
Mark Simon Stein, Victor Kalff, Scott G Williams, Declan G Murphy, Peter G Colman, Michael S Hofman
The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer. Endocrine oncology (Bristol, England) 4 (1) (2024)

volume 3, number 1, 2023

Sofia Maria Lider Burciulescu, Caren Randon, Frederic Duprez, Wouter Huvenne, David Creytens, Kathleen B M Claes, Robin de Putter, Guy T'Sjoen, Corin Badiu, Bruno Lapauw
Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma. Endocrine oncology (Bristol, England) 3 (1) (2023)
Trinidad Raices, María Luisa Varela, Adriana María Belén Abiuso, Elba N Pereyra, Carolina Mondillo, Omar P Pignataro, María Fernanda Riera
Curcumin effects on Leydig cell functions and potential therapeutic uses. Endocrine oncology (Bristol, England) 3 (1) (2023)
Nele F Lenders, Peter E Earls, Warrick J Inder, Ann I McCormack
The evolution in pituitary tumour classification: a clinical perspective. Endocrine oncology (Bristol, England) 3 (1) (2023)
Macarena Contreras Angulo, Belén García Izquierdo, Laura Armengod Grao, Nuria Palacios
Thrombotic microangiopathy associated with lenvatinib therapy. Endocrine oncology (Bristol, England) 3 (1) (2023)
Molly Endicott, Chrissie Thirlwell, Amy P Webster
Exploring genetic loci of type 2 diabetes and cancer: a review. Endocrine oncology (Bristol, England) 3 (1) (2023)
Prabesh Khatiwada, Ujjwal Rimal, Mamata Malla, Zhengyang Han, Lirim Shemshedini
Peptides disrupting TM4SF3 interaction with AR or AR-V7 block prostate cancer cell proliferation. Endocrine oncology (Bristol, England) 3 (1) (2023)
Lucinda M Gruber, Steven N Hart, Louis James Maher Iii
Succinate dehydrogenase variants in paraganglioma: why are B subunit variants 'bad'? Endocrine oncology (Bristol, England) 3 (1) (2023)
Jose Viana Lima, Nilza M Scalissi, Kelly C de Oliveira, Susan C Lindsey, Caroline Olivati, Elisa Napolitano Ferreira, Claudio E Kater
Germline genetic variants in pheochromocytoma/paraganglioma: single-center experience. Endocrine oncology (Bristol, England) 3 (1) (2023)
Katherine A English, Rajesh V Thakker, Kate E Lines
The role of DNA methylation in human pancreatic neuroendocrine tumours. Endocrine oncology (Bristol, England) 3 (1) (2023)
Justo P. Castaño
Endocrine Oncology : the home for translational research in cancer and hormones. Endocrine oncology (Bristol, England) 3 (1) (2023)
Yuko Matsuo, Kenji Ashida, Ayako Nagayama, Kanoko Moritaka, Mizuki Gobaru, Junichi Yasuda, Naoyuki Ogasawara, Hirofumi Kurose, Katsuaki Chikui, Shimpei Iwata, Yukihiro Inoguchi, Nao Hasuzawa, Seiichi Motomura, Tsukasa Igawa, Masatoshi Nomura
Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma. Endocrine oncology (Bristol, England) 3 (1) (2023)
Benjamin J Worrall, Alexander James Papachristos, Ahmad Aniss, Anthony Glover, Stan B Sidhu, Roderick John Clifton-Bligh, Diana Learoyd, Venessa H M Tsang, Matti Gild, Bruce G Robinson, Mark S Sywak
Lobectomy and completion thyroidectomy rates increase after the 2015 American Thyroid Association Differentiated Thyroid Cancer Guidelines update. Endocrine oncology (Bristol, England) 3 (1) (2023)
Joel George, John K Ramage, Benjamin White, Rajaventhan Srirajaskanthan
The role of serotonin inhibition within the treatment of carcinoid syndrome. Endocrine oncology (Bristol, England) 3 (1) (2023)
Gido Snaterse, Johannes Hofland, Bruno Lapauw
The role of 11-oxygenated androgens in prostate cancer. Endocrine oncology (Bristol, England) 3 (1) (2023)
Vineeth K Sukrithan, Prachi Jain, Manisha H Shah, Bhavana Konda
Kinase inhibitors in thyroid cancers. Endocrine oncology (Bristol, England) 3 (1) (2023)
Stéphanie Larose, Dany Rioux, Roula Albadine, André Lacroix
Ectopic ACTH Cushing's syndrome caused by a large-cell neuroendocrine lung carcinoma responding to desmopressin. Endocrine oncology (Bristol, England) 3 (1) (2023)

volume 3, number 1, 2022

Annabelle G Hayes, Masoumeh G Shirazi, Anand Thiyagarajah, David J Torpy, Sunita M C De Sousa
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma. Endocrine oncology (Bristol, England) 3 (1) (2022)

volume 2, number 1, 2022

Kiyoshi Takagi, Mio Yamaguchi, Minoru Miyashita, Hironobu Sasano, Takashi Suzuki
Diverse role of androgen action in human breast cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Poh Shean Wong, Subashini Rajoo, Hairuddin Achmad Sankala, Mohamed Badrulnizam Long Bidin
Unusual presentation of lung carcinoma with pituitary metastasis: a challenging diagnosis and sodium management dilemmas. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sean T McSweeney, Hannah E Bergom, Anna Prizment, Susan Halabi, Nima Sharifi, Charles Ryan, Justin H Hwang
Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Darran Mc Donald, M Sherlock, C J Thompson
Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Christie G Turin, Molly M Crenshaw, Lauren Fishbein
Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes. Endocrine oncology (Bristol, England) 2 (1) (2022)
Alexander Kreze, Matěj Homer, Tereza Barešová, Kristina Klemperová
Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab. Endocrine oncology (Bristol, England) 2 (1) (2022)
Krishna Vikneson, Tariq Haniff, May Thwin, Ahmad Aniss, Alex Papachristos, Mark Sywak, Anthony Glover
Tumour volume is a predictor of lymphovascular invasion in differentiated small thyroid cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sara Coelho, Cláudia Costa, Ana Paula Santos, Pedro Souteiro, Joana Oliveira, Júlio Oliveira, Isabel Azevedo, Isabel Torres, Maria José Bento
Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive center. Endocrine oncology (Bristol, England) 2 (1) (2022)
Syed Ehsanullah, Nikolaos A Trikalinos
Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sunita M C De Sousa
Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocrine oncology (Bristol, England) 2 (1) (2022)
Marcus Vetter, Karin M Rothgiesser, Qiyu Li, Hanne Hawle, Wolfgang Schönfeld, Karin Ribi, Salome Riniker, Roger von Moos, Andreas Trojan, Elena Kralidis, Mathias Fehr, Andreas Müller, Beat Thürlimann, null null
SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. Endocrine oncology (Bristol, England) 2 (1) (2022)
Anna Stroud, Pearl Dhaliwal, Richard J Harvey, Raquel Alvarado, Benjamin P Jonker, Mark J Winder, Jessica W Grayson, Ann I McCormack
Low but not undetectable early postoperative nadir serum cortisol predicts sustained remission in Cushing's disease. Endocrine oncology (Bristol, England) 2 (1) (2022)
Nathan J Graham, Joshua D Smith, Tobias Else, Gregory J Basura
Paragangliomas of the head and neck: a contemporary review. Endocrine oncology (Bristol, England) 2 (1) (2022)
Sylvia L Asa, Shereen Ezzat
Pituitary carcinoma: reclassification and implications in the NET schema. Endocrine oncology (Bristol, England) 2 (1) (2022)
Yixi Bi, Safwaan Adam, Viktoria Chatzimavridou, Paul Lorigan, Yinglai Huang
Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis abnormalities: a clinical case. Endocrine oncology (Bristol, England) 2 (1) (2022)
Erina Iwabuchi, Yasuhiro Miki, Takashi Suzuki, Hironobu Sasano
Visualization of the protein-protein interactions of hormone receptors in hormone-dependent cancer research. Endocrine oncology (Bristol, England) 2 (1) (2022)
Donatella Treppiedi, Rosa Catalano, Federica Mangili, Giovanna Mantovani, Erika Peverelli
Role of filamin A in the pathogenesis of neuroendocrine tumors and adrenal cancer. Endocrine oncology (Bristol, England) 2 (1) (2022)